Immunotherapy
Entity.
- Evidence
- 742 documents · 167 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 11 Mar 2026, last seen 27 Oct 2026
- Measured
- 5% of mentions say something specific about it; the rest only name it
- As of
- 28 Oct 2026
Where this comes from
- Seoul Economic Daily · 2026-10-27 · Samsung Bioepis Keytruda Biosimilar Matches Original in Phase 1 Trial (opens the source in a new tab)
- Medical Xpress · 2026-10-27 · Exploring the potential of immunotherapy in early-stage triple-negative breast cancer (opens the source in a new tab)
- European Medical Journal · 2026-10-25 · PSGL-1 Shows Promise as Cancer immunotherapy Target (opens the source in a new tab)
- OncoDaily · 2026-10-25 · PERSEE: Adding Chemotherapy to Pembrolizumab Significantly Extends PFS in PD-L1–High NSCLC (opens the source in a new tab)
- OncoDaily · 2026-10-25 · OptiTROP-Lung06: Sac-TMT Plus Pembrolizumab Outperforms Chemoimmunotherapy in PD-L1–Negative NSCLC (opens the source in a new tab)
- Medical Daily · 2026-10-25 · Adding Belzutifan or a CTLA-4 Drug Failed to Beat Keytruda Plus Lenvima in 1,688-Patient Kidney Cancer Trial (opens the source in a new tab)
- medRxiv Oncology · 2026-10-24 · USFDA Oncology Drug Approvals from 2014- 2025: Comparing non-immunotherapy and immunotherapy approvals, their endpoints, and their efficacy. (opens the source in a new tab)
- Peter Attia · 2026-10-24 · Personalized medicine comes to cancer immunotherapy (opens the source in a new tab)
- The Medical News · 2026-10-24 · Personalized mRNA cancer vaccine cuts melanoma recurrence risk when added to immunotherapy (opens the source in a new tab)
- The Medical News · 2026-10-24 · Nearly one third of patients with advanced melanoma saw tumors disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy (opens the source in a new tab)
- All News Releases · 2026-10-24 · Likang Life Sciences Showcases Personalized Cancer Immunotherapy and Global Ambitions at Abu Dhabi Future Health Summit 2026 (opens the source in a new tab)
What is claimed about it
- Reported by two: Reported by two sources that did not copy each other.
- Could not check: We could not count this claim's sources, so we do not say how well it is supported.
- Personalized mRNA cancer vaccine cuts melanoma recurrence risk when added to immunotherapy Reported by two · first reported 24 Oct 2026
- New biomarker framework proposed for immunotherapy in microsatellite-stable colorectal cancer Could not check · first reported 23 Oct 2026